The Chairman decided the record date of 2022 first issuance of RSU according to the resolution Of BOD

Announcement on behalf of AP Biosciences that the BOD resolved to convene 2022 first extraordinary General Shareholders' Meeting

OBI-822 “Cancer Immunotherapy by Immune Activation or Immune Modulation via Globo Series Antigens“ was granted by USPTO

Announcement on behalf of AP Biosciences of the resignation of its institutional director

OBI PHARMA INC. to attend investor conference hosted by MASTERLINK SECURITIES

Announcement of AP Biosciences’ full receipt of cash capital increase in 2022 and the reference date of capital increase

Announcement of the expiration of AP Biosciences’ 2022 cash capital increase call period

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to TFDA

Announcement on behalf of AP Biosciences that application for Phase I human clinical trial of Bispecific Antibody, AP203, has been granted by US FDA

Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons